- Lobbying
- sanofi AND us
Lobbying Arrangements Results for 'Sanofi Us'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to coverage and pricing of various pharmaceutical drugs under Federal health care programs; Issues related to pricing of insulin products, and costs to patients of pharmaceuticals. |
Sanofi US
|
RICCHETTI INCORPORATED | |||
Details FDA issues, Drug Pricing Issues, Vaccine Issues Medicare Part D issues |
Sanofi US Services, Inc.
|
American Capitol Group | |||
Details Medicare. |
Sanofi US Services Inc f/k/a sanofi-aventis U.S. Inc.
|
Hogan Lovells US LLP | |||
Details Generic drug approval issues before Congress and the Executive Branch |
Sanofi-Aventis US
Pharmaceutical company |
BROWNSTEIN HYATT FARBER SCHRECK, P.C. | |||
Details Pandemic influenza, biodefense, and other vaccine-related issues. |
sanofi pasteur
Vaccine production |
DLA Piper Rudnick Gray Cary US LLP | |||
Details Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
Sanofi US Services Inc.
|
Thorn Run Partners | |||
Details Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act. General is... |
Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.)
|
PARRY, ROMANI, DECONCINI & SYMMS | |||
Details issues in PPACA, health reform that might impact pharmaceuticals and veterans health care |
Sanofi-Aventis, US, Inc.
|
McKenna Long & Aldridge LLP | |||
Details Issues related to over the counter Monograph reform, vaccines, and the Pandemic and All-Hazards Preparedness Act. |
Sanofi US
|
NVG, LLC | |||
Details -Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development ... |
Sanofi US Services, Inc.
|
FOLEY HOAG LLP | |||
Details Vaccine related issues and general biologics issues, including issues related to Zika and diabetes solutions. |
Sanofi US
|
TWENTY-FIRST CENTURY GROUP, INC. | |||
Details Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation," a strengthened and permanent U.S. R&D tax credit, inclu... |
Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.)
|
CANFIELD & ASSOCIATES, INC. | |||
Details Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH fund... |
Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.)
|
TCH Group, LLC | |||
Details H. Res 295 and S. Res 243 - Resolution to promote increased awareness, diagnosis, and treatment of atrial fibrillation, and to address high mortality and morbidity and to reduce hospitalizations. -... |
sanofi-aventis U.S., Inc
Pharmaceutical Company |
Ms. Camille Bonta | |||
Details H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 20... |
Sanofi US Services Inc.
|
Capitol Hill Strategies, LLC | |||
Details Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related ... |
Sanofi US Services Inc.
|
in-house lobbying | |||
Details Education about the necessity and safety of vaccines and their role in preventing childhood disease. Issues related to pharmaceutical pricing in general (no specific legislation) |
Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.)
|
Knight Capitol Consultants | |||
Details DOJ policy regarding off label communications. |
Medical Information Working Group
|
SIDLEY AUSTIN LLP | |||
Details FDA drug approval process S.1695-Biologics Price Competition and Innovation Act |
SANOFI-AVENTIS US
|
BROWNSTEIN HYATT FARBER SCHRECK, LLP | |||
Details Enforcement priorities and policies regarding communications by pharmaceutical and medical device manufacturers about their medical products. |
Medical Information Working Group
|
Ropes & Gray, LLP | |||
Details Assist Congress in formulating preparedness for pandemic (avian flue) influenza outbreak; provide informatin on vaccine safety; and work to cover vaccines under the Vaccine Injury Compensation Prog... |
Sanofi Pasteur, Inc.
A US based manufacturer of vaccines and the only US manufacturer of injectable flu vaccine |
The Washington Group, Inc. | |||
Details Pandemic influenza, vaccine-related issues. Tax issues impacting pharmacies. H.R. 475, to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definitio... |
SANOFI PASTEUR
|
DLA Piper LLP (US) | |||
Details Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; value of prescript... |
Sanofi US Services Inc.
|
Capitol Counsel LLC | |||
Details Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biotechnology industry |
Sanofi US Services, Inc.
|
BGR Government Affairs | |||
Details Issues related to health care, the Food and Drug Administration (FDA), Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutica... |
Sanofi US Services Inc.
|
Crossroads Strategies, LLC | |||
Details IRA implementation, transparency, vaccines, coverage and access IRA implementation, supply chain integrity, 340B, orphan drugs, newborn screening, expanded access, transparency, drug shortages, dru... |
Sanofi US Services, Inc. (formerly known as Genzyme Corporation)
|
TARPLIN, DOWNS & YOUNG, LLC |